SINGLE-AF Trial Links Newer Blood Thinners to Lower Stroke Risk

Atrial fibrillation patients taking direct oral anticoagulants experience a 69 percent lower risk of adverse cardiovascular events compared to those receiving no anticoagulant therapy, according to clinical trial findings published in the New England Journal of Medicine. The study results offer new data for patients facing an intermediate risk of stroke, a population where treatment recommendations have historically remained less definitive.

• Patients with atrial fibrillation at intermediate stroke risk saw a 69 percent reduction in primary endpoint events when treated with direct oral anticoagulants.
• Serious clinical events occurred in 0.5 percent of the direct oral anticoagulant group compared to 1.5 percent in the untreated control group during the 24-month study window.
• Major bleeding rates showed no statistically significant increase, occurring in 0.3 percent of the treated participants versus 0.5 percent of untreated participants.

SINGLE-AF Trial Compares Anticoagulants with No Therapy

The findings emerged from the SINGLE-AF trial, presented during a Hot Line session at the ESC Congress 2026. The study enrolled individuals diagnosed with atrial fibrillation who carried an intermediate risk of stroke, classified by a CHA2DS2-VASc score of 1 for men or 2 for women. Participants were randomized in a 1:1 ratio. One arm received oral anticoagulant treatment using either apixaban at 5 milligrams twice daily or rivaroxaban at 20 milligrams once daily, while the control arm received no anticoagulation therapy over the 24-month observation period.

Reduction in Ischemic Stroke Without Major Bleeding Risks

The primary endpoint combined stroke, systemic embolism, major bleeding, and cardiovascular death. Investigators documented these adverse events in 0.5 percent of patients assigned to direct oral anticoagulants, contrasted with 1.5 percent among participants receiving no therapy. The trial data indicated that the overall risk reduction derived primarily from a drop in ischemic strokes. Ischemic stroke developed in 0.1 percent of patients taking the newer blood thinners, compared to 1.1 percent in the untreated group. Safety endpoints demonstrated that major bleeding occurred in 0.3 percent of the direct oral anticoagulant cohort and 0.5 percent of the untreated participants, confirming that the stroke-reduction benefit accrued without a simultaneous surge in hemorrhage hazards.

Current clinical frameworks from major medical societies recommend direct oral anticoagulants for nonvalvular atrial fibrillation patients based on risk stratification scores, though intermediate categories have allowed for clinical discretion. Guidance from the European Society of Cardiology proposes gender-neutral evaluation criteria, recommending these medications for patients with a CHA2DS2-VASc score of 2 or higher, while maintaining treatment consideration for individuals with a score of 1. Beyond standard direct oral anticoagulants, alternative strategies continue to develop. For patients carrying absolute contraindications to anticoagulant medications, such as a history of intracranial hemorrhage, clinical teams evaluate left atrial appendage occlusive devices like the Watchman or Amplatzer Amulet as mechanical alternatives for stroke mitigation.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.